04:09 PM EST, 02/27/2025 (MT Newswires) -- Cytokinetics ( CYTK ) reported a Q4 net loss Thursday of $1.26 per diluted share, narrowing from the loss of $1.38 a year earlier.
Analysts polled by FactSet expected a loss of $1.19.
Revenue in the three months ended Dec. 31 jumped to $16.9 million from $1.67 million a year earlier.
Analysts surveyed by FactSet expected $1.7 million.